METHOTREXATE

Burkitt Leukemia

Fred Hutchinson Cancer CenterSmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

6 Active assets in the Burkitt Leukemia cohort.

Asset / Sponsor	Phase	Rating
Cytosin-Arabinosid M.D. Anderson Cancer Center	Phase 2	B
Inno-206 M.D. Anderson Cancer Center	Phase 2	B
DEXAMETHASONE M.D. Anderson Cancer Center	Phase 2	B
Cyclophosphamide Fred Hutchinson Cancer Center	Phase 2	B
VINCRISTINE SULFATE M.D. Anderson Cancer Center	Phase 2	B

View all 11 →

Same molecule, other indications

METHOTREXATE is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

acute promyelocytic leukemiaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.